Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | DRD2 | P14416 | 4/20 | 0.42 |
| ▸ | DRD4 | P21917 | 3/20 | 0.42 |
| ▸ | DRD3 | P35462 | 3/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29299830 | 0.88 | FOLH1 (0.56) | LMNAFOLH1SMN1; SMN2MAPK1ALDH1A1 | |
| SCHEMBL29300488 | 0.83 | FOLH1 (0.50) | LMNAFOLH1SMN1; SMN2MAPK1ALDH1A1 | |
| SCHEMBL29299663 | 0.82 | FOLH1 (0.53) | LMNAFOLH1SMN1; SMN2ALDH1A1HTT | |
| SCHEMBL29299810 | 0.81 | FOLH1 (0.70) | LMNAFOLH1HTT | |
| SCHEMBL29300532 | 0.79 | FOLH1 (0.44) | LMNAFOLH1SMN1; SMN2 | |
| SCHEMBL29300499 | 0.78 | DPP7 (0.44) | FOLH1SMN1; SMN2DRD2DRD4 | |
| SCHEMBL29300563 | 0.75 | FOLH1 (0.38) | FOLH1SMN1; SMN2ITGB3 | |
| SCHEMBL24590552 | 0.75 | SMN1; SMN2 (0.50) | LMNAFOLH1SIGMAR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL29299615 | 0.75 | NPC1 (0.54) | LMNASMN1; SMN2MAPK1ALDH1A1HTT | |
| SCHEMBL10137835 | 0.74 | NPC1 (0.60) | LMNASMN1; SMN2MAPK1ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | LMNA 3809/4885FOLH1 335/4885SIGMAR1 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.